Every Form 4 that TNF Pharmaceuticals, Inc. (TNFA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TNFA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNFA filings page.
Q/C TECHNOLOGIES, INC. director Chelsea Sierra Voss reported a small open-market purchase of common stock through a Roth IRA. The filing shows an indirect acquisition of 1,753 shares at $3.15 per share, bringing her Roth IRA holdings to 61,555 shares and her separate direct holdings to 239,900 shares.
Q/C Technologies, Inc. director Stephen Friscia received a grant of employee stock options covering 50,000 shares of common stock. The options have an exercise price of $5.00 per share and expire on April 13, 2036. All 50,000 options were held directly after the grant and are subject to expiration if he stops serving the company.
Q/C Technologies, Inc. director Chelsea Sierra Voss received an employee stock option grant covering 50,000 shares of common stock. The options have a $5.00 per share exercise price and expire on April 13, 2036. Following this grant, she holds options for 50,000 shares directly. The options may expire earlier if she stops being employed by or providing services to the company.
Q/C Technologies, Inc. reported that Chief Medical Officer Mitchell Glass received a grant of employee stock options on common stock. The award covers 50,000 options, each giving the right to buy one share of common stock at an exercise price of $5.00 per share.
These options were granted on April 13, 2026 and expire on April 13, 2036. Following this grant, Glass holds 50,000 stock options directly. The options may expire earlier if he ceases to be employed by or provide services to the company.
Q/C Technologies director Billy Joe White received a grant of employee stock options for 50,000 shares of Common Stock. The options have a conversion or exercise price of $5.00 per share, were granted on April 13, 2026, and expire on April 13, 2036. Following this award, he holds 50,000 derivative securities directly, which are subject to expiration if he stops being employed by or providing services to the company.
Q/C TECHNOLOGIES, INC. director Bruce Bernstein received an award of employee stock options covering 50,000 shares of common stock on April 13, 2026. The options have an exercise price of $5.00 per share and were granted at a price of $0.00 per option.
The options are exercisable into 50,000 shares of common stock and expire on April 13, 2036. According to the filing, the options are subject to expiration if Bernstein ceases to be employed by, or to provide services to, the company.
Q/C Technologies, Inc. reported that Executive Chairman Joshua Silverman received new equity awards. He was granted employee stock options for 100,000 shares of common stock at an exercise price of $5.00 per share, expiring on April 13, 2036, and will hold 50,000 options after this grant.
He was also awarded 162,162 shares of common stock in the form of Restricted Stock Units issued under an executive compensation agreement dated April 13, 2026. The RSUs vested immediately upon grant, bringing his direct common stock holdings to 262,191 shares.
Q/C Technologies director Chelsea Sierra Voss reported new equity awards. On January 16, 2026, she received 212,500 shares of common stock as restricted stock units under a consulting agreement and 25,000 additional RSU shares tied to her appointment to the board. Both RSU grants vest in four equal quarterly installments if she continues providing services.
She also received an employee stock option for 212,500 shares of common stock at an exercise price of $5.097 per share, vesting quarterly on the same schedule. Following these awards, she beneficially owns 239,900 shares of common stock directly and 59,802 shares indirectly through a Roth IRA, plus 212,500 stock options.